智通财经APP获悉，真健康医疗-B(02697)涨超9% ，截至发稿，涨8.53%，报412.4港元，成交额844.6万港元。
据悉，真健康医疗是一家专注于经皮穿刺手术及消融手术机器人18A企业。核心产品为经皮穿刺手术机器人，共四个型号（THS1、TH-S、TH-SPro及TH-SA），均已获得国家药监局三类注册证，获批应用于肺部及腹部穿刺。同时，公司正在将TH-S1的适应症扩展至腹膜后病变。根据灼识咨询的资料，按2025年经皮穿刺手术机器人的收入计量，公司在中国位居首位，市场份额为28.0%。
值得一提的是，恒生指数公司或于8月25日公布半年度指数调整结果，所有变动将于9月7日起生效，届时沪深交易所会相应调整港股通可投资标的范围。华泰证券预测真健康医疗有望纳入港股通。财务数据看，2024年及2025年，公司收入分别为179.1万元及1217.8万元，2025年同比增长579.9%。增长主要来自核心产品销量增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.